Copyright indiatimes
iStockImage used for representation Glenmark Pharmaceuticals on Tuesday said it will launch a generic medication, used to treat high acid levels in the body, in the US market. Glenmark Pharmaceuticals Inc., USA, is gearing up to launch 8.4 per cent Sodium Bicarbonate Injection in a single-dose vial, the Mumbai-based drug firm said in a regulatory filing. The company's product is therapeutically equivalent to Abbott Laboratories' product, it added. The company said it expects to commence distribution of the product in the US market this month. According to IQVIA sales data for the 12-month period ending August 2025, the medication achieved annual sales of around USD 63.8 million.Live Events Shares of Glenmark Pharmaceuticals ended 2.72 per cent down to Rs 1,846.45 apiece on the BSE.Add as a Reliable and Trusted News Source Add Now! (You can now subscribe to our Economic Times WhatsApp channel) Read More News onglenmark pharmaceuticalsGlenmark PharmaceuticalsSodium Bicarbonate Injectionmetabolic acidosis treatmentgeneric drug launchUS pharmaceutical marketAbbott Laboratorieshigh acid levels in the bodyIQVIA sales datapharmaceutical industry news (Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online....moreless (You can now subscribe to our Economic Times WhatsApp channel)Read More News onglenmark pharmaceuticalsGlenmark PharmaceuticalsSodium Bicarbonate Injectionmetabolic acidosis treatmentgeneric drug launchUS pharmaceutical marketAbbott Laboratorieshigh acid levels in the bodyIQVIA sales datapharmaceutical industry news(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.) Subscribe to The Economic Times Prime and read the ET ePaper online....moreless
